Next Phase Newsletter

The firm is a venture capital firm based in Western Europe, established in 2020, focused on enabling technologies within life sciences and healthcare. The firm invests from an early-stage fund and typically makes initial investments starting around €1M, with the capacity to deploy additional capital through follow-on rounds totaling several million euros per company. The firm invests across Seed to Series B stages and aims to be a meaningful investor, often leading or co-leading rounds while also participating in syndicates. The firm maintains a regional focus on Western Europe and has an active investment pace with multiple portfolio companies and exits to date.  

The firm focuses on diagnostics, medical devices, and digital health opportunities. The firm does not invest in therapeutics and avoids invasive devices, particularly higher-risk regulatory classifications. The firm evaluates companies with regulatory progress and early clinical validation, including those at or around initial clinical stages.  

From a company and management team perspective, the firm does not impose strict requirements but takes a hands-on approach to investing. The firm typically requires board representation and works closely with portfolio companies to support growth, development, and commercialization. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

A global healthtech and life sciences investment fund has a presence across North America and the Middle East. The firm manages significant assets and partners with entrepreneurs developing transformative science and technology to improve healthcare outcomes. The investment team is multidisciplinary, bringing together expertise across science, medicine, engineering, and venture investing, and actively supports portfolio companies through a platform-oriented approach.  

The firm invests across the full company lifecycle through multiple strategies. An early-stage strategy focuses on company creation, academic spinouts, and Seed to Series A investments in disruptive technologies. A complementary growth strategy targets later-stage companies in expansion rounds, pre-IPO financings, or pivotal clinical development. The firm supports companies from early innovation through commercialization and scaling.  

The firm invests broadly across therapeutics, medical devices, diagnostics, digital health, and life science tools. Key areas of interest include precision and personalized medicine, multi-omics, next-generation cell and gene therapies, engineered biology, and digital transformation of diagnostics and care delivery. For biotech and medtech, the firm is particularly interested in companies with early clinical proof of concept and near-term value inflection points. In diagnostics and tools, the firm targets breakthrough technologies approaching commercialization. In digital health, the firm focuses on companies with demonstrated revenue traction and scalability.  

From a company and management team perspective, the firm seeks strong, execution-oriented teams capable of solving complex problems and achieving product-market fit. The firm prioritizes opportunities addressing significant unmet medical needs with clear pathways to market access and long-term value creation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

The firm is a globally diversified healthcare venture capital firm headquartered in Asia, with a strong presence across North America, Europe, and other international markets. The firm maintains a globally balanced portfolio and partners with a broad network of institutional, clinical, and commercial stakeholders. In addition to capital, the firm provides hands-on support in strategy, cross-border expansion, manufacturing partnerships, and distribution, helping portfolio companies scale internationally and navigate complex healthcare ecosystems.  

The firm invests across early- to growth-stage opportunities, with a focus on medical devices, digital health, healthcare services, and AI-enabled solutions. Key areas of interest include oncology and radiotherapy, ophthalmology, brain health and neuromodulation, cardiovascular diseases, women’s and children’s health, and chronic disease management such as diabetes. The firm prioritizes technologies that address meaningful clinical needs and have the potential for broad global impact.  

From a company and management team perspective, the firm seeks to partner with mission-driven founders developing innovative healthcare solutions. The firm does not impose strict requirements on management teams but values integrity, strong execution capability, and the ability to scale across international markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

 
The firm is a life sciences venture capital firm based in the United States focused on early- and growth-stage biotech and pharmaceutical companies. The firm manages substantial assets and typically makes initial investments in the low- to mid-single-digit millions, primarily through equity, with occasional use of convertible structures. The firm seeks to take meaningful ownership positions and plays an active role in the development of its portfolio companies. While the firm invests across the U.S., it has a particular interest in opportunities outside of the major biotech hubs.  

The firm focuses exclusively on therapeutic companies within the biotechnology sector. The firm is generally agnostic to modality and indication but prioritizes assets with novel mechanisms of action that address clear unmet medical needs. The firm typically invests in companies ranging from late preclinical through Phase II clinical development. The firm does not invest in diagnostics, medical devices, digital health, or healthcare IT.  

From a company and management team perspective, the firm does not impose strict requirements but typically requires board representation in connection with its investments to enable active collaboration and strategic involvement throughout company development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

A family office-backed private investment firm founded in the mid-2000s maintains a global presence across North America and Europe. The firm leverages deep operating and investment experience to partner with growth-oriented companies across technology-enabled sectors. The firm deploys flexible capital through venture, growth equity, and private equity strategies, investing across stages from early-stage through later growth rounds. The firm maintains a diversified global portfolio and partners with management teams to drive scalable, long-term value creation.  

The firm invests across technology-enabled consumer and enterprise businesses, as well as healthcare and select life sciences opportunities. Areas of activity include consumer platforms, digital services, biotech, and healthcare services. The firm targets companies with defensible business models, strong competitive positioning, and the ability to scale effectively. The investment approach emphasizes long-term growth, sustainable differentiation, and cross-sector innovation.  

From a company and management team perspective, the firm partners with founders and executives who demonstrate operational excellence, clear strategic vision, and the ability to scale businesses significantly. The firm emphasizes long-term relationships and provides more than capital, offering strategic guidance, operational support, and access to an extensive network. The firm invests through both equity and structured transactions and works collaboratively with leadership teams to support commercialization, product expansion, and organizational growth across global markets. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

The firm is a healthcare technology company developing and commercializing AI-powered, laboratory-based diagnostics for early detection and prevention of cancer and chronic diseases. Following a recent financing event tied to public market activity, the firm is allocating a portion of capital toward strategic investments and potential acquisitions. The firm is particularly interested in identifying companies that could serve as future acquisition targets, with a focus on those generating early revenues.  

The firm is actively evaluating opportunities across diagnostics, digital health, and medical devices that address chronic disease detection, longevity, and nutrition-based interventions. Areas of particular interest include solutions that advance “food-as-medicine” approaches and technologies that support prevention and long-term health optimization.  

From a company and management team perspective, the firm does not impose strict requirements but prioritizes companies with demonstrated commercial traction and solutions aligned with its broader platform and strategic roadmap. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology

The firm is a life sciences-focused investment arm of a broader innovation platform, established recently and based in Europe. The firm is actively deploying capital from an early-stage fund and typically makes initial investments in the low single-digit millions. The firm is open to syndicating with co-investors to support portfolio company growth. While the firm has a current geographic emphasis on regional opportunities, it maintains a global investment outlook.  
 
The firm focuses on early-stage biotechnology opportunities emerging from academic and research environments, with a strong emphasis on translational science progressing toward first-in-human studies. The firm prioritizes therapeutic programs supported by robust preclinical data, including modalities such as peptide-based therapeutics. Areas of interest include indications like chronic and nerve-related conditions, among others. The firm seeks programs with a clear and credible path to clinical entry within a defined development timeline, supported by validated targets, strong in vivo data, and early safety work. While therapeutics is the primary focus, the firm actively collaborates with external partners to advance high-potential biological innovations.  
 
From a company and management team perspective, the firm seeks academic founders and early-stage scientific teams developing differentiated therapeutic candidates with strong translational potential. The firm prioritizes opportunities with defensible intellectual property, rigorous preclinical validation, and well-defined development strategies toward IND-enabling studies. The firm works closely with portfolio companies by providing scientific, regulatory, and operational support and engages with teams capable of executing early development milestones. The firm is open to leading or co-leading rounds and partnering with additional investors to support clinical and commercial advancement. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, entrepreneurship, finance, health, investing, technology